(Q36269226)

13 August 2017

1 reference

title

Immunosuppressive therapy in rheumatic disease (English)

2 references

13 August 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A16187

17 March 2022

Immunosuppressive Therapy in Rheumatic Disease (English)

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

16 October 2022

Bardana EJ Jr

2

1 reference

13 August 2017

B. Pirofsky

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A16187

17 March 2022

E. J. Bardana

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A16187

17 March 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16187

17 March 2022

1 March 1977

1 reference

full work available at URL

13 August 2017

https://api.elsevier.com/content/article/PII:S0025712516313426?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

https://api.elsevier.com/content/article/PII:S0025712516313426?httpAccept=text/plain

17 March 2022

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Medical Clinics of North America

17 March 2022

published in

1 reference

13 August 2017

volume

61

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

419-437

1 reference

Methotrexate therapy in polymyositis

13 August 2017

cites work

The clinical course of the proliferative and membranous forms of lupus nephritis.

1

volume

32

page(s)

536

0 references

2

73

929

The clinical course of the proliferative and membranous forms of lupus nephritis (English)

Baldwin

1970

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Azathioprine in steroid-insensitive nephropathy

17 March 2022

3

49

789

Azathioprine in steroid insensitive nephropathy (English)

Bardana

1970

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Dermatomyositis and malignancy. A review of the literature

17 March 2022

7

84

68

Dermatomyositis and malignancy (English)

Barnes

1976

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

The systemic lesions of malignant rheumatoid arthritis

17 March 2022

10

16

197

The systemic lesions of malignant rheumatoid arthritis (English)

Bevans

1954

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Treatment of Wegener's granulomatosis with Imuran

17 March 2022

14

42

314

Treatment of Wegener's granulomatosis with Imuran (English)

Bouroncle

1967

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis

17 March 2022

16

10

37

Comparison of azathioprine, prednisone and heparin alone or combined in treating lupus nephritis (English)

Cade

1973

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Renal histology and clinical course of systemic lupus erythematosus. A prospective study

17 March 2022

19

16

670

Renal histology and clinical course of systemic lupus erythematosus. A prospective study (English)

Cheatum

1973

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Systemic (allergic?) vasculitis.

17 March 2022

20

54

54

Allergy Grand Rounds: Systemic (allergic?) vasculitis (English)

Claman

1974

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

A Controlled Trial of Cyclophosphamide in Rheumatoid Arthritis

17 March 2022

21

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis.

17 March 2022

24

2

763

Comparisons of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis (English)

Currey

1974

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Treatment of Lupus Nephritis with Prednisone and Combined Prednisone and Azathioprine

17 March 2022

28

77

829

Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine (English)

Donadio

1972

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine

17 March 2022

29

17

573

Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine (English)

Progressive lupus glomerulonephritis. Treatment with prednisone and combined prednisone and cyclophosphamide

Donadio

0 references

30

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

The distribution and character of glomerular deposits in systemic lupus erythematosus

16 October 2022

31

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Azathioprine and prednisone in the treatment of adults with lupus nephritis. Clinical, histological, and immunological changes with therapy

16 October 2022

32

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Favorable outcome in diffuse proliferative glomerulonephritis of systemic lupus erythematosus

16 October 2022

33

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

16 October 2022

Letter: Lupus nephritis

34

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Successful renal transplantation in Wegener's granulomatosis

16 October 2022

36

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Cyclophosphamide in Treatment of Systemic Lupus Erythematosus: 7 Years' Experience

16 October 2022

37

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Dermatomyositis in the Transvaal and its occurrence in the Bantu

16 October 2022

38

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Long-term cyclophosphamide therapy in rheumatoid arthritis

16 October 2022

39

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis

16 October 2022

41

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Long-term follow-up study of periarteritis nodosa.

16 October 2022

42

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Effects of salicylate and phenobarbital on lymphocyte proliferation and function

16 October 2022

43

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Cyclophosphamide: Use in Practice

16 October 2022

46

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Long-term maintenance therapy with azathioprine in systemic lupus erythematosus

16 October 2022

47

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

CYCLOPHOSPHAMIDE-PREDNISONE THERAPY OF LETHAL MIDLINE GRANULOMA

16 October 2022

48

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Cyclophosphamide in systemic lupus erythematosus

16 October 2022

49

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients

16 October 2022

50

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Further Experience with Azathioprine in Rheumatoid Arthritis

16 October 2022

51

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Prognostic indices in lupus nephritis

16 October 2022

53

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

The Use of Alkylating Agents in the Treatment of Wegener's Granulomatosis

16 October 2022

54

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

The treatment of rheumatoid arthritis and necrotizing vasculitis with penicillamine

16 October 2022

56

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Successful renal transplantation in progressive systemic sclerosis

16 October 2022

59

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Vascular lesions in rheumatoid arthritis

16 October 2022

60

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Transfer factor in cellular immunity

16 October 2022

61

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Levamisole-mediated restoration of cellular immunity in peripheral blood lymphocytes of patients with immunodeficiency diseases

16 October 2022

62

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

The prolonged treatment of rheumatoid arthritis with cortisone and corticotropin

16 October 2022

63

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Treatment of psoriatic arthritis with azaribine

16 October 2022

64

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Treatment of Lupus Nephritis With Azathioprine

16 October 2022

66

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Treatment of dermatomyositis with methotrexate

16 October 2022

67

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Azathioprine in Rheumatoid Arthritis

16 October 2022

68

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Increased incidence of malignancy during chronic renal failure

16 October 2022

69

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Polymyositis and Dermatomyositis: Combined Methotrexate and Corticosteroid Therapy

16 October 2022

72

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Cyclophosphamide protection in nzb/nzw disease. Mechanisms and therapeutic regimens

16 October 2022

73

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Cyclophosphamide Therapy in Wegener's Granulomatosis

16 October 2022

74

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

The effect of oxisuran on human immunological responsiveness

16 October 2022

78

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Editorials: Immunosuppressive therapy in lupus erythematosus

16 October 2022

80

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Hemodialysis and kidney transplantation for renal failure from scleroderma

16 October 2022

81

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Guidelines for the use of cytotoxid drugs in rheumatic diseases

16 October 2022

82

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Cyclophosphamide in the treatment of systemic lupus erythematosus

16 October 2022

83

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Letter: Normothermic complete hepatic vascular exclusion for extensive resection of the liver

16 October 2022

86

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Treatment of patients with systemic lupus erythematosus including nephritis with chlorambucil

16 October 2022

87

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Treatment of corticosteroid-resistant polymyositis with methotrexate.

16 October 2022

88

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Cyclophosphamide in lupus nephritis: a controlled trial

16 October 2022

89

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis

16 October 2022

91

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Azathioprine in the treatment of systemic lupus erythematosus. A controlled study

16 October 2022

92

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Controlled trial of cyclophosphamide in rheumatoid arthritis

16 October 2022

94

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

[Antilymphocyte serum therapy in human autoimmune diseases]

16 October 2022

95

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

ANTIMETABOLITE THERAPY IN MIDLINE LETHAL GRANULOMA

16 October 2022

97

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Immunosuppressive agents in lupus nephritis: a critical analysis

16 October 2022

98

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

16 October 2022

Wegener's granulomatosis

99

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

Progression from minimal or focal to diffuse proliferative lupus nephritis

16 October 2022

100

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)31342-6

16 October 2022

Identifiers

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16187

9 October 2022

1 reference